Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Martin

Showing results (261-270 of 278) with videos related to

Pageof 28
Sort By:
Oncotarget|April 21, 2017
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerAranzazu Fernandez-Martinez, Tomás Pascual, Giuseppe Perrone, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
JCO Precision Oncology|April 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study AnalysisEric Hahnen, Jan Hauke, Karen Gelmon, et al.
The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.
Breast (Edinburgh, Scotland)|October 7, 2022
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trialJavier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial CohortCarsten Denkert, Sivaramakrishna Rachakonda, Anika Pehl, et al.
Nature Communications|May 26, 2021
Non-productive angiogenesis disassembles Aß plaque-associated blood vesselsMaria I Alvarez-Vergara, Alicia E Rosales-Nieves, Rosana March-Diaz, et al.
Cancers|July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate CancerEnrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Pageof 28

Showing results (261-270 of 278) with videos related to

Sort By:
Pageof 28
Oncotarget|April 21, 2017
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerAranzazu Fernandez-Martinez, Tomás Pascual, Giuseppe Perrone, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
JCO Precision Oncology|April 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study AnalysisEric Hahnen, Jan Hauke, Karen Gelmon, et al.
The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.
Breast (Edinburgh, Scotland)|October 7, 2022
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trialJavier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial CohortCarsten Denkert, Sivaramakrishna Rachakonda, Anika Pehl, et al.
Nature Communications|May 26, 2021
Non-productive angiogenesis disassembles Aß plaque-associated blood vesselsMaria I Alvarez-Vergara, Alicia E Rosales-Nieves, Rosana March-Diaz, et al.
Cancers|July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate CancerEnrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Pageof 28